Delta Asset Management’s Cumberland Pharmaceuticals CPIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-12,000
Closed -$72K 572
2018
Q4
$72K Hold
12,000
0.01% 188
2018
Q3
$68K Buy
12,000
+1,000
+9% +$5.89K 0.01% 214
2018
Q2
$67K Hold
11,000
0.01% 208
2018
Q1
$73K Hold
11,000
0.01% 191
2017
Q4
$81K Sell
11,000
-1,000
-8% -$7.36K 0.01% 187
2017
Q3
$85K Hold
12,000
0.01% 171
2017
Q2
$84K Hold
12,000
0.01% 172
2017
Q1
$83K Hold
12,000
0.01% 170
2016
Q4
$67K Hold
12,000
0.01% 196
2016
Q3
$60K Hold
12,000
0.01% 206
2016
Q2
$55K Hold
12,000
0.01% 211
2016
Q1
$53K Hold
12,000
0.01% 217
2015
Q4
$63K Hold
12,000
0.01% 203
2015
Q3
$69K Buy
12,000
+1,000
+9% +$6.23K 0.01% 186
2015
Q2
$79K Hold
11,000
0.01% 184
2015
Q1
$73K Hold
11,000
0.01% 198
2014
Q4
$66K Hold
11,000
0.01% 200
2014
Q3
$54K Hold
11,000
0.01% 214
2014
Q2
$50K Hold
11,000
0.01% 227
2014
Q1
$50K Hold
11,000
0.01% 226
2013
Q4
$56K Hold
11,000
0.01% 207
2013
Q3
$50K Hold
11,000
0.01% 216
2013
Q2
$56K Buy
+11,000
New +$54.7K 0.01% 199

Other funds holding CPIX

Delta Asset Management's CPIX Position: Q1 2019 in Review

Delta Asset Management sold out of Cumberland Pharmaceuticals (CPIX) in Q1 2019, closing a stake of 12,000 shares — an estimated $72K sold.

Delta Asset Management first reported a position in CPIX in Q2 2013 and held it in 23 quarters. The position peaked at $85K in Q3 2017. 23 funds tracked by Wall St. Rank hold CPIX as of Q1 2019.

  • Delta Asset Management reported no remaining Cumberland Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Delta Asset Management sold 12,000 Cumberland Pharmaceuticals shares in Q1 2019, an estimated $72K.
  • Delta Asset Management first reported a position in Cumberland Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Delta Asset Management's Cumberland Pharmaceuticals position peaked at $85K in Q3 2017.
  • 23 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2019.

Based on Delta Asset Management's 13F filing for Q1 2019, filed 30 Apr 2019.